
Akari Therapeutics Plc (AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
시가총액
$20K
수익
$0
P/E 비율
N/A
주가순자산비율
0.00
부채자본비율
0.15
배당 수익률
0.00%
마지막 업데이트: June 7 at 24:02:05